Medication info
Trulicity M Tablets 2.5/500mg (Linagliptin, Metformin Hydrochloride)

Trulicity M Tablets 2.5/500mg (Linagliptin, Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Linagliptin›2.5mg / 1 tabletMetformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
Boryung Pharmaceuticals Co., Ltd.
Appearance
Bright yellow, double convex, oval film-coated tablet
Packaging
30 tablets/bottle, 60 tablets/bottle, 100 tablets/bottle, 200 tablets/bottle
Approval status
Active

MFDS item code 201902369 · Approved 2019.04.17 · Insurance code 641907000

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes
Who takes it
Adults
Adult dose
The dose of this medicine should be determined according to each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently treated with metformin: For patients who have not previously received pharmacological treatment for diabetes and whose blood glucose is inadequately controlled with monotherapy, the initial dose is 1 tablet of this medicine 2.5/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 2.5/1000 mg twice daily. 2. Switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should take the same doses of linagliptin and metformin as those they had been taking as the initial dose. 3. Patients whose blood glucose is inadequately controlled with combination therapy of insulin and metformin: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered in combination with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Patients Requiring Caution). No studies have been conducted to evaluate the safety and efficacy of switching to this medicine in patients previously treated with another oral antihyperglycemic agent. Any change in the treatment regimen for type 2 diabetes may alter blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who have no other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Because the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine must be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients in Whom This Medicine Must Not Be Used).

Ingredients

Manufacturer
Boryung Pharmaceuticals Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes

View approved original text

This medication is used as an adjunct to diet and exercise to help control blood sugar levels in patients with type 2 diabetes who are using linagliptin and metformin together.

How to take

Adult dose

The dose of this medicine should be determined according to each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently treated with metformin: For patients who have not previously received pharmacological treatment for diabetes and whose blood glucose is inadequately controlled with monotherapy, the initial dose is 1 tablet of this medicine 2.5/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 2.5/1000 mg twice daily. 2. Switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should take the same doses of linagliptin and metformin as those they had been taking as the initial dose. 3. Patients whose blood glucose is inadequately controlled with combination therapy of insulin and metformin: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered in combination with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Patients Requiring Caution). No studies have been conducted to evaluate the safety and efficacy of switching to this medicine in patients previously treated with another oral antihyperglycemic agent. Any change in the treatment regimen for type 2 diabetes may alter blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who have no other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Because the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine must be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients in Whom This Medicine Must Not Be Used).

Precautions

This medication helps control blood sugar levels. However, there are several precautions to consider when taking this medication. First, patients with poor kidney function should not take this medication, as decreased kidney function can lead to accumulation of the drug in the body which can be hazardous. Furthermore, patients with liver dysfunction or cardiovascular disease should use this medication with caution, as these conditions may exacerbate drug side effects. A rare side effect known as lactic acidosis may occur, which can lead to a dangerously excessive accumulation of lactic acid in the body. Symptoms such as abdominal pain, muscle pain, and difficulty breathing should prompt immediate consultation with a doctor. There is also a risk of hypoglycemia, especially when taken alongside insulin or sulfonylurea medications, so blood sugar levels should be monitored frequently. It is advisable for pregnant women or women who may become pregnant, and nursing mothers to avoid using this medication. Additionally, patients with acute alcohol intoxication or alcohol dependence should avoid taking this medication, as alcohol can increase the risk of drug side effects. For patients undergoing surgery or receiving contrast tests with radioiodine, the use of this medication should be discontinued for a certain period before and after the tests, and it should be resumed only after reevaluating kidney function. This medication is not recommended for children or adolescents as its safety and effectiveness have not been sufficiently established. Elderly patients may experience a decline in kidney function, thus regular monitoring of kidney function and dose adjustment is necessary. When taking this medication, there is a possibility of interaction with other drugs, so it is essential to consult a doctor or pharmacist if taking other medications. Finally, this medication should be kept out of the reach of children and stored away from moisture.

Side effects

  • Lactic acidosis
  • hypoglycemia
  • taste disturbance
  • cough
  • decreased appetite
  • diarrhea
  • constipation
  • nausea
  • pancreatitis
  • vomiting
Show 140 more
  • abdominal pain
  • oral ulcer formation
  • abnormal liver function tests
  • hepatitis
  • pruritus
  • erythema
  • rash
  • vesicular pemphigoid
  • severe and disabling arthralgia
  • rhabdomyolysis
  • increased lipase
  • increased amylase
  • nasopharyngitis
  • hypersensitivity
  • angioedema
  • urticaria
  • decreased and deficient vitamin B12
  • oral ulcers
  • abnormal liver function
  • constipation
  • upper abdominal pain
  • enterocolitis
  • intestinal obstruction
  • gastroenteritis
  • shingles
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuronitis
  • sepsis
  • pneumonia
  • decreased appetite
  • dehydration
  • hyperglycemia
  • cerebral infarction
  • speech disorder
  • Alzheimer's dementia
  • chest pain
  • fever
  • facial swelling
  • fatigue
  • chronic obstructive pulmonary disease
  • asthma
  • diabetic foot
  • skin lesions
  • acute leukemia
  • basal cell carcinoma
  • non-small cell lung cancer
  • malignant pericardial effusion
  • gastric cancer
  • rectal cancer
  • pancreatic cancer
  • meniscal injury
  • pneumoconiosis
  • congestive heart failure
  • angina
  • acute myocardial infarction
  • unstable angina
  • cardiac arrest
  • diabetic retinopathy
  • acute kidney injury
  • end-stage renal disease
  • acute cholecystitis
  • cholangitis
  • dizziness
  • kidney transplant failure
  • anxiety
  • mood disorder
  • insomnia
  • depression
  • contusion
  • bone contusion
  • concussion
  • bone fracture
  • hand fracture
  • laceration
  • palpitations
  • dry eye
  • glaucoma
  • cataract
  • ocular discomfort
  • allergic conjunctivitis
  • polyuria
  • proteinuria
  • stress urinary incontinence
  • hematuria
  • hypotension
  • flushing
  • hepatic steatosis
  • cholelithiasis
  • hearing loss
  • erectile dysfunction
  • thyroid goiter
  • anemia
  • dizziness
  • sensory loss
  • pruritus
  • hypertension
  • benign prostatic hyperplasia
  • confusion state
  • nocturia
  • dermatitis
  • angina
  • acute myocardial infarction
  • unstable angina
  • diarrhea
  • stomatitis
  • mediastinitis
  • vitreous hemorrhage
  • fever
  • ligament sprain
  • flank pain
  • myelodysplastic syndrome
  • vocal cord polyp
  • gingivitis
  • dyspepsia
  • upper abdominal pain
  • stomatitis
  • increased blood creatinine
  • facial swelling
  • back pain
  • osteoarthritis
  • limb pain
  • rotator cuff syndrome
  • headache
  • drowsiness
  • nosebleed
  • oropharyngeal pain
  • voice disorder
  • difficulty breathing
  • nasal bleeding
  • dizziness
  • dyslipidemia
  • hypercholesterolemia
  • thyroid nodule
  • papilloma
  • pruritus
  • insomnia
  • depression
  • hypertension

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to avoid exposure to air or moisture, and it is best kept at a cool room temperature between 1 to 30 degrees Celsius. This way, the efficacy of the medication can be maintained and degradation can be prevented.

Appearance and packaging

Appearance

Bright yellow, double convex, oval film-coated tablet

Package unit

30 tablets/bottle, 60 tablets/bottle, 100 tablets/bottle, 200 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.